by Dr. Nicholas John Murgolo, Senior Principal Scientist, Merck Research Laboratories
Since emergence of COVID-19, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has spread globally. Early efforts to identify efficacious therapeutics focused on drug repurposing screens to identify compounds with antiviral activity in cellular systems. These screens yielded intriguing hits, but use of non-human immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of SARS-CoV-2 evolves, current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 entry will be discussed for developing the most appropriate toolbox to support current and future drug discovery efforts. The genome and other therapeutic strategies will be discussed as well.
Dr. Murgolo received a Biochemistry Ph.D. in 1987 from Stevens Institute of Technology (Hoboken NJ). Following a postdoctoral appointment in Medical Biochemistry at The Rockefeller University (NYC), in 1989 he joined Schering-Plough, which merged with Merck in 2009. Initially working in Biotechnology and Protein Molecular Modeling, he was a founding member of the Bioinformatics group in 1996. A Senior Principal Scientist in the Genetics group, he supports Infectious Diseases and Bioprocess Research. He is also an Adjunct Professor at Stevens where he teaches Biochemistry and Bioinformatics.
Zoom Link: https://stevens.zoom.us/j/96137792722